Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

TCRTAlaunos Therapeutics, Inc.

Nasdaq · CIK 0001107421
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts348

Identity from submissions API

NameAlaunos Therapeutics, Inc.
CIK0001107421
TickersTCRT
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN841475642
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(346) 355-4099
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • ZIOPHARM ONCOLOGY INC (2005-09-20T04:00:00.000Z → 2022-01-04T05:00:00.000Z)
  • EASYWEB INC (2001-02-13T05:00:00.000Z → 2005-09-19T04:00:00.000Z)
Business address
501 E LAS OLAS BLVD
SUITE 300
FORT LAUDERDALE
FL
33301
FL
Mailing address
501 E LAS OLAS BLVD
SUITE 300
FORT LAUDERDALE
FL
33301
FL

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1299 filing rows loaded from submissions recent; extra archives: CIK0001107421-submissions-001.json (296 filings, 2001-02-13 to 2010-03-30).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 10-Q 10-Q 0001193125-26-463638 001-33038 261561764 34 7582567 1 1
2026-11-13 PRE 14A PRE 14A 0001193125-26-461060 001-33038 261554226 34 3068995 1 1
2026-11-13 S-3 S-3 0001193125-26-458953 333-300017 261548663 33 812332 1 1
2026-10-23 8-K 8-K 8.01 0001193125-26-430507 001-33038 261482582 34 177634 1 1
2026-10-21 8-K 8-K 3.01,9.01 0001193125-26-427890 001-33038 261476050 34 187928 1 1
2026-10-15 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001193805-26-001370 005-79364 261464108 34 13660
2026-10-15 3 xslF345X06/ownership.xml 0001683168-26-007900 23438
2026-10-15 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001683168-26-007898 005-79364 261463068 34 51746
2026-10-13 8-K 8-K 1.01,2.01,3.02,5.02,5.03,7.01,9.01 0001193125-26-419829 001-33038 261455182 34 16113075 1 1
2026-10-09 8-K 8-K 3.01 0001193125-26-419154 001-33038 261453231 34 188570 1 1
2026-10-08 4 4 0001193125-26-417970 4866
2026-10-08 4 4 0001193125-26-417971 6515
2026-10-08 4 4 0001193125-26-417969 6451
2026-10-08 4 4 0001193125-26-417974 4790
2026-09-22 8-K 8-K 1.01,8.01,9.01 0001193125-26-397996 001-33038 261397195 34 1289539 1 1
2026-09-21 424B3 424B3 0001193125-26-396777 333-289748 261394545 33 1301825
2026-09-17 8-K 8-K 3.03,5.03 0001193125-26-393462 001-33038 261385061 34 347365 1 1
2026-08-14 10-Q 10-Q 0001193125-26-352421 001-33038 261282627 34 4851430 1 1
2026-08-11 4 4 0001193125-26-344682 4863
2026-07-27 4 4 0001193125-26-318114 4787
2026-07-27 4 4 0001193125-26-318105 4863
2026-07-27 4 4 0001193125-26-318103 6448
2026-07-27 4 4 0001193125-26-318100 6512
2026-07-06 S-8 S-8 0001193125-26-295169 333-297265 261153939 33 273473 1 1
2026-07-02 4 4 0001193125-26-295004 4921
2026-06-29 8-K 8-K 8.01,9.01 0001193125-26-286914 001-33038 261131465 34 249316 1 1
2026-06-17 4 4 0001193125-26-274305 4921
2026-05-27 4 4 0001193125-26-241999 4920
2026-05-26 8-K 8-K 8.01,9.01 0001193125-26-238237 001-33038 261016928 34 24745742 1 1
2026-05-18 8-K 8-K 8.01,9.01 0001193125-26-227921 001-33038 26990829 34 195967 1 1
2026-05-15 10-Q 10-Q 0001193125-26-227272 001-33038 26989949 34 4291022 1 1
2026-05-01 4 4 0001193125-26-201557 6455
2026-05-01 4 4 0001193125-26-201489 6483
2026-05-01 4 4 0001193125-26-201474 4824
2026-04-30 10-K/A 10-K/A 0001193125-26-197838 001-33038 26927203 34 1111644 1 1
2026-04-15 8-K 8-K 3.01 0001193125-26-157126 001-33038 26864533 34 167563 1 1
2026-03-31 10-K 10-K 0001193125-26-134720 001-33038 26822614 34 9353305 1 1
2026-03-05 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0002094682-26-000002 005-79364 26724895 34 658863
2026-03-02 8-K 8-K 8.01,9.01 0001193125-26-084084 001-33038 26703326 34 232101 1 1
2026-02-24 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0002094682-26-000001 005-79364 26672655 34 530071
2026-01-15 4 4 0001193125-26-014117 4686
2026-01-15 4 4 0001193125-26-014116 6346
2026-01-15 4 4 0001193125-26-014115 6318
2026-01-08 8-K 8-K 1.02,3.03,8.01,9.01 0001193125-26-007054 001-33038 26517513 34 580908 1 1
2025-12-23 8-K 8-K 8.01 0001193125-25-331147 001-33038 251601737 34 218944 1 1
2025-12-11 424B8 424B8 0001193125-25-316216 333-291002 251565796 33 340716
2025-12-05 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0002094682-25-000003 005-79364 251552663 34 317994
2025-11-26 4 4 0001193125-25-301033 6371
2025-11-26 4 4 0001193125-25-301026 6347
2025-11-26 4 4 0001193125-25-301025 4687
2025-11-14 10-Q 10-Q 0001193125-25-282988 001-33038 251486469 34 5791609 1 1
2025-11-07 S-3/A S-3/A 0001193125-25-272465 333-289748 251463176 33 519453
2025-10-31 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0002094682-25-000002 005-79364 251439872 34 2899151
2025-10-30 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0002094682-25-000001 005-79364 251437475 34 2346748
2025-10-22 S-1 S-1 0001193125-25-245483 333-291002 251408310 33 632031 1 1
2025-10-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-099624 005-79364 251398247 34 6811
2025-10-02 S-3/A S-3/A 0001193125-25-227248 333-289748 251366290 33 494588
2025-10-01 CORRESP filename1.htm 0001193125-25-227249 10058
2025-09-17 UPLOAD filename1.pdf 0000000000-25-010141 333-289748 43765
2025-09-09 S-3/A S-3/A 0001193125-25-198562 333-289748 251301410 33 853861
2025-09-08 CORRESP filename1.htm 0001193125-25-198564 30336
2025-09-05 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001213900-25-085149 005-79364 251297530 34 11420
2025-09-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-084258 005-79364 251291850 34 8485
2025-09-02 UPLOAD filename1.pdf 0000000000-25-009437 333-289748 44256
2025-08-21 S-3 S-3 0001193125-25-184432 333-289748 251238205 33 762740 1 1
2025-08-20 4 4 0000950170-25-110531 7132
2025-08-20 4 4 0000950170-25-110530 5380
2025-08-20 8-K 8-K 8.01 0000950170-25-110484 001-33038 251237720 34 161056 1 1
2025-08-14 10-Q 10-Q 0000950170-25-108887 001-33038 251219362 34 5522108 1 1
2025-07-22 8-K 8-K 5.02 0000950170-25-097591 001-33038 251140774 34 159363 1 1
2025-07-17 4 4 0000950170-25-096674 7860
2025-07-17 3 3 0000950170-25-096673 21308
2025-07-17 8-K 8-K 5.02,9.01 0000950170-25-096656 001-33038 251131481 34 169187 1 1
2025-07-10 8-K 8-K 3.03,5.07,9.01 0000950170-25-095029 001-33038 251116611 34 272959 1 1
2025-07-07 4 4 0000950170-25-094387 8840
2025-07-07 4 4 0000950170-25-094386 8891
2025-07-07 4 4 0000950170-25-094383 5790
2025-07-02 8-K 8-K 3.01,5.02 0000950170-25-093263 001-33038 251102737 34 177710 1 1
2025-07-01 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0000921895-25-001912 005-79364 251097994 34 23094
2025-06-26 4 4 0000950170-25-090589 5389
2025-06-26 4 4 0000950170-25-090587 12667
2025-06-26 8-K 8-K 1.01,7.01,9.01 0000950170-25-090202 001-33038 251075206 34 772201 1 1
2025-06-26 8-K 8-K 1.01,3.02,3.03,5.03,9.01 0000950170-25-090201 001-33038 251075205 34 512038 1 1
2025-06-24 424B3 424B3 0001193125-25-145739 333-266841 251069344 33 444331
2025-06-10 8-K 8-K 1.01,3.02,9.01 0000950170-25-083913 001-33038 251035291 34 210513 1 1
2025-05-23 8-K 8-K 1.01,3.02,9.01 0000950170-25-077064 001-33038 25983230 34 1122715 1 1
2025-05-21 ARS ARS 0001193125-25-123682 001-33038 25970998 34 1397411
2025-05-21 DEFA14A DEFA14A 0001193125-25-123680 001-33038 25970994 34 1083347
2025-05-21 DEF 14A DEF 14A 0001193125-25-123677 001-33038 25970987 34 2171338 1 1
2025-05-15 10-Q 10-Q 0000950170-25-072709 001-33038 25953925 34 3971674 1 1
2025-05-14 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001213900-25-043211 005-79364 25944714 34 15784
2025-05-09 PRE 14A PRE 14A 0001193125-25-116509 001-33038 25928598 34 2185441 1 1
2025-04-30 10-K/A 10-K/A 0000950170-25-061207 001-33038 25896578 34 1176164 1 1
2025-04-18 8-K 8-K 5.02 0000950170-25-055903 001-33038 25850758 34 169453 1 1
2025-04-15 4 4 0000950170-25-054436 8961
2025-04-15 4 4 0000950170-25-054432 5304
2025-04-15 4 4 0000950170-25-054429 4897
2025-04-15 8-K 8-K 5.02 0000950170-25-054309 001-33038 25840270 34 184701 1 1
2025-04-14 8-K 8-K 1.01,1.02,3.02,3.03,5.03,9.01 0000950170-25-053523 001-33038 25834350 34 684872 1 1
2025-04-11 8-K 8-K 3.01,8.01 0000950170-25-053325 001-33038 25832754 34 160642 1 1
2025-04-01 4 4 0000950170-25-048554 5618
2025-04-01 4 4 0000950170-25-048492 5532
2025-04-01 4 4 0000950170-25-048491 5548
2025-03-31 10-K 10-K 0000950170-25-047758 001-33038 25793519 34 9776575 1 1
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-019905 005-79364 25620473 34 145638
2025-01-03 4 4 0000950170-25-001257 6202
2024-12-31 144 xsl144X01/primary_doc.xml 0001959173-24-008881 001-33038 241593708 33 13713
2024-11-14 SC 13G/A SC 13G/A 0001193125-24-258550 005-79364 241461989 34 91699
2024-11-14 10-Q 10-Q 0000950170-24-126793 001-33038 241457791 34 4231878 1 1
2024-10-10 8-K 8-K 1.02,2.02,9.01 0000950170-24-113960 001-33038 241363873 34 186646 1 1
2024-08-16 4 4 0000950170-24-098103 5576
2024-08-16 4 4 0000950170-24-098045 5548
2024-08-14 10-Q 10-Q 0000950170-24-097142 001-33038 241209141 34 4634976 1 1
2024-07-17 8-K/A 8-K/A 3.03,5.03,9.01 0000950170-24-084024 001-33038 241120682 34 234436 1 1
2024-07-17 8-K/A 8-K/A 8.01,9.01 0000950170-24-084023 001-33038 241120681 34 228769 1 1
2024-07-16 8-K 8-K 5.03 0000950170-24-083765 001-33038 241118645 34 217390 1 1
2024-07-16 8-K 8-K 8.01 0000950170-24-083764 001-33038 241118641 34 213014 1 1
2024-06-21 8-K 8-K 4.01,9.01 0000950170-24-076333 001-33038 241061263 34 214293 1 1
2024-06-12 8-K 8-K 3.03,5.03,5.07,9.01 0000950170-24-072534 001-33038 241039118 34 269088 1 1
2024-06-10 4 4 0000950170-24-071401 7605
2024-06-10 4 4 0000950170-24-071400 5576
2024-06-10 4 4 0000950170-24-071399 5449
2024-06-10 4 4 0000950170-24-071396 5495
2024-05-15 10-Q 10-Q 0000950170-24-060075 001-33038 24947421 34 5210656 1 1
2024-04-26 ARS ARS 0001193125-24-118282 001-33038 24884799 34 2249594
2024-04-26 DEFA14A DEFA14A 0001193125-24-118265 001-33038 24884741 34 351876
2024-04-26 DEF 14A DEF 14A 0001193125-24-118247 001-33038 24884655 34 1074361
2024-04-15 PRE 14A PRE 14A 0001193125-24-096391 001-33038 24845521 34 1074349
2024-04-01 10-K 10-K 0000950170-24-038868 001-33038 24805539 34 10458053 1 1
2024-02-28 3 3 0000950170-24-022569 20403
2024-02-22 8-K 8-K 5.02 0001193125-24-042903 001-33038 24665621 34 148611 1 1
2024-02-20 8-K e619290_8k-at.htm 8.01,9.01 0001193805-24-000251 001-33038 24653217 34 194594 1 1
2024-02-14 SC 13G/A d10943920_13g-a.htm 0000919574-24-001345 005-79364 24635115 34 106443
2024-02-13 SC 13G/A SC 13G/A 0001193125-24-033902 005-79364 24627299 34 94452
2024-02-01 8-K e619211_8k-at.htm 5.03,9.01 0001193805-24-000111 001-33038 24584374 34 238850 1 1
2024-01-29 8-K e619210_8k-at.htm 8.01,9.01 0001193805-24-000103 001-33038 24570559 34 235303 1 1
2024-01-23 4 4 0000950170-24-006700 5551
2024-01-22 8-K 8-K 5.02 0001193125-24-012201 001-33038 24549200 34 146456 1 1
2024-01-03 4 4 0000950170-24-001195 7812
2024-01-03 3 3 0000950170-24-001161 15378
2024-01-02 8-K 8-K 5.02,7.01 0001193125-24-000240 001-33038 24500289 34 154173 1 1
2023-12-28 8-K 8-K 5.02 0001193125-23-305187 001-33038 231523034 34 145592 1 1
2023-12-22 8-K 8-K 5.02 0001193125-23-301802 001-33038 231507187 34 141721 1 1
2023-11-15 8-K 8-K 5.02 0001193125-23-277541 001-33038 231409038 34 180093 1 1
2023-11-14 8-K 8-K 2.02,3.01,9.01 0001193125-23-276662 001-33038 231401610 34 218339 1 1
2023-11-14 10-Q 10-Q 0000950170-23-063354 001-33038 231401599 34 7322025 1 1
2023-09-28 8-K 8-K 5.02 0001193125-23-245602 001-33038 231289414 34 138548 1 1
2023-09-05 4 4 0000950170-23-046504 5564
2023-09-01 144 xsl144X01/primary_doc.xml 0001974078-23-000135 001-33038 231231551 33 4499
2023-08-14 10-Q 10-Q 0000950170-23-042486 001-33038 231171236 34 7297796 1 1
2023-08-14 8-K 8-K 2.02,9.01 0001193125-23-212358 001-33038 231170447 34 187226 1 1
2023-07-05 8-K 8-K 3.01 0001193125-23-181966 001-33038 231069114 34 140966 1 1
2023-06-12 8-K 8-K 3.03,5.03,5.07,9.01 0001193125-23-165305 001-33038 231008260 34 184532 1 1
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014923 5543
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014920 5589
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014918 5569
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014916 5568
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014913 5670
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014910 5590
2023-05-10 10-Q 10-Q 0000950170-23-020088 001-33038 23904348 34 7043217 1 1
2023-05-10 8-K 8-K 2.02,9.01 0001193125-23-140010 001-33038 23904305 34 197287 1 1
2023-04-25 DEFA14A DEFA14A 0001193125-23-115504 001-33038 23845747 34 1101289
2023-04-25 DEF 14A DEF 14A 0001193125-23-115492 001-33038 23845699 34 2328177
2023-04-19 4 FORM 4 SUBMISSION 0000899243-23-011453 7948
2023-04-19 3 FORM 3 SUBMISSION 0000899243-23-011452 8904
2023-04-14 PRE 14A PRE 14A 0001193125-23-102248 001-33038 23821947 34 2317796
2023-04-04 8-K 8-K 1.01 0001193125-23-091011 001-33038 23799232 34 146436 1 1
2023-04-03 8-K 8-K 1.01 0001193125-23-088948 001-33038 23790681 34 141786 1 1
2023-03-30 8-K 8-K 5.02,9.01 0001193125-23-084520 001-33038 23777169 34 177439 1 1
2023-03-17 4 FORM 4 SUBMISSION 0000899243-23-009002 5662
2023-03-17 4 FORM 4 SUBMISSION 0000899243-23-009001 5635
2023-03-17 4 FORM 4 SUBMISSION 0000899243-23-009000 5646
2023-03-17 4 FORM 4 SUBMISSION 0000899243-23-008999 5645
2023-03-17 4 FORM 4 SUBMISSION 0000899243-23-008998 5633
2023-03-07 10-K 10-K 0000950170-23-006377 001-33038 23711040 34 12747700 1 1
2023-03-07 8-K 8-K 2.02,9.01 0001193125-23-062072 001-33038 23711015 34 205671 1 1
2023-02-14 SC 13G/A SC 13G/A 0001193125-23-038503 005-79364 23626458 34 78003
2023-02-14 SC 13G/A d9926632_13g-a.htm 0000919574-23-001518 005-79364 23626286 34 109294
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015233 005-79364 23602183 34 13105
2023-01-20 SC 13G/A Alaunos_Therapeutics_Inc.txt 0000093751-23-000019 005-79364 23539021 34 8405
2023-01-09 8-K FORM 8-K 7.01,8.01,9.01 0001193125-23-004224 001-33038 23516768 34 6027883 1 1
2023-01-04 8-K 8-K 3.01 0001193125-23-001563 001-33038 23507406 34 142620 1 1
2022-12-01 4 FORM 4 SUBMISSION 0000899243-22-037275 6812
2022-12-01 4 FORM 4 SUBMISSION 0000899243-22-037274 14257
2022-11-30 8-K 8-K 1.01,8.01,9.01 0001193125-22-295491 001-33038 221436257 34 449616 1 1
2022-11-30 424B5 FORM 424(B)(5) 0001193125-22-295486 333-266841 221436246 33 651821
2022-11-28 424B5 FORM 424(B)(5) 0001193125-22-293389 333-266841 221425418 33 655592
2022-11-14 10-Q 10-Q 0000950170-22-024695 001-33038 221380279 34 10528149 1 1
2022-11-14 8-K 8-K 2.02,7.01,9.01 0001193125-22-283649 001-33038 221380113 34 7468375 1 1
2022-11-07 8-K 8-K 7.01,9.01 0001193125-22-278556 001-33038 221363801 34 164498 1 1
2022-09-30 8-K 8-K 8.01,9.01 0001193125-22-254857 001-33038 221282327 34 7504062 1 1
2022-09-21 8-K 8-K 7.01,9.01 0001193125-22-248092 001-33038 221255074 34 170030 1 1
2022-09-19 4 FORM 4 SUBMISSION 0000899243-22-031464 11395
2022-09-19 4 FORM 4 SUBMISSION 0000899243-22-031462 5654
2022-09-19 4 FORM 4 SUBMISSION 0000899243-22-031460 11224
2022-09-19 4 FORM 4 SUBMISSION 0000899243-22-031459 5601
2022-09-07 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-09-07 16:00:00 9999999995-22-002609 333-266841 221232428 33 1856
2022-09-07 424B5 424B5 0001193125-22-240009 333-266841 221231369 33 444418
2022-09-06 8-K 8-K 8.01,9.01 0001193125-22-238444 001-33038 221226955 34 162692 1 1
2022-09-02 CORRESP filename1.htm 0001193125-22-237887 5889
2022-09-01 4 FORM 4 SUBMISSION 0000899243-22-030186 4991
2022-08-31 S-3/A S-3/A 0001193125-22-235248 333-266841 221218437 33 763513
2022-08-24 8-K 8-K 7.01,9.01 0001193125-22-228590 001-33038 221192039 34 158585 1 1
2022-08-19 UPLOAD filename1.pdf 0000000000-22-008920 40300
2022-08-16 4 FORM 4 SUBMISSION 0000899243-22-028813 5680
2022-08-15 3 FORM 3 SUBMISSION 0000899243-22-028659 9797
2022-08-15 10-Q 10-Q 0000950170-22-017225 001-33038 221162340 34 7925243 1 1
2022-08-15 8-K 8-K 2.02,9.01 0001193125-22-220540 001-33038 221162283 34 185004 1 1
2022-08-12 S-3 S-3 0001193125-22-220066 333-266841 221161066 33 1647952
2022-08-04 8-K 8-K 7.01,9.01 0001193125-22-212664 001-33038 221137716 34 159367 1 1
2022-07-13 8-K 8-K 8.01 0001193125-22-192331 001-33038 221080218 34 139961 1 1
2022-07-08 SC 13G us98973p1012_070822.txt 0000834237-22-010175 005-79364 221074971 34 12303
2022-06-27 8-K 8-K 1.01,7.01,9.01 0001193125-22-182171 001-33038 221041618 34 166969 1 1
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024011 6938
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024006 12703
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024005 14690
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023997 6938
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023988 12703
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023987 14690
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023985 9817
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023978 6936
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-023977 15627
2022-06-17 8-K 8-K 3.03,5.03,5.07,9.01 0001193125-22-176544 001-33038 221024338 34 179745 1 1
2022-05-24 8-K 8-K 7.01,9.01 0001193125-22-158062 001-33038 22954076 34 4907123 1 1
2022-05-16 10-Q 10-Q 0000950170-22-009942 001-33038 22925468 34 6051674 1 1
2022-05-16 8-K 8-K 2.02,9.01 0001193125-22-150889 001-33038 22925463 34 182666 1 1
2022-05-02 8-K 8-K 7.01,9.01 0001193125-22-136842 001-33038 22882463 34 163530 1 1
2022-05-02 8-K 8-K 8.01,9.01 0001193125-22-135461 001-33038 22879540 34 162602 1 1
2022-04-27 DEFA14A DEFA14A 0001193125-22-123724 001-33038 22860258 34 553713
2022-04-27 DEF 14A DEF 14A 0001193125-22-123703 001-33038 22860123 34 936640
2022-04-15 PRE 14A PRE 14A 0001193125-22-106850 001-33038 22830334 34 1410768
2022-04-08 3 FORM 3 SUBMISSION 0000899243-22-014358 10293
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013119 11232
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013117 11212
2022-03-30 S-8 S-8 0001193125-22-089868 333-263983 22786920 33 88234
2022-03-30 10-K 10-K 0000950170-22-004972 001-33038 22783178 34 14100462 1 1
2022-03-30 8-K 8-K 2.02,9.01 0001193125-22-088653 001-33038 22783172 34 195309 1 1
2022-03-18 8-K 8-K 3.01 0001193125-22-079589 001-33038 22753250 34 143158 1 1
2022-03-17 8-K 8-K 1.01,7.01,9.01 0001193125-22-077889 001-33038 22746868 34 5193839 1 1
2022-02-14 SC 13G/A d9181468_13g-a.htm 0000919574-22-001633 005-79364 22634450 34 108137
2022-02-11 SC 13G ZIOPHARM_ONCOLOGY_INC.txt 0000093751-22-000305 005-79364 22619850 34 8598
2022-02-11 SC 13G/A SCHEDULE 13G 0001674751-22-000002 005-79364 22618803 34 447024
2022-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-22-018959 005-79364 22611288 34 13142
2022-02-03 SC 13G/A us98973p1012_020222.txt 0000834237-22-005462 005-79364 22585713 34 13547
2022-01-26 8-K 8-K 5.03,7.01,8.01,9.01 0001193125-22-017681 001-33038 22555692 34 5167962 1 1
2022-01-04 8-K 8-K 1.01,2.03,3.02 0001193125-22-001682 001-33038 22505805 34 193858 1 1
2021-12-27 4 FORM 4 SUBMISSION 0000899243-21-049739 5460
2021-12-13 4 FORM 4 SUBMISSION 0000899243-21-047850 5608
2021-12-09 3 FORM 3 SUBMISSION 0000899243-21-047494 3060
2021-11-29 3 FORM 3 SUBMISSION 0001209191-21-067034 8552
2021-11-17 4 FORM 4 SUBMISSION 0001209191-21-065138 6219
2021-11-08 10-Q 10-Q 0000950170-21-003463 001-33038 211388024 34 9150902 1 1
2021-11-05 8-K 8-K 5.02 0000950170-21-003235 001-33038 211384585 34 163878 1 1
2021-10-12 SC 13G/A MILLER VALUE PARTNERS, LLC 0001085146-21-002718 005-79364 211318214 34 47759
2021-10-04 4 FORM 4 SUBMISSION 0001209191-21-059131 8012
2021-10-01 8-K 8-K 5.02 0000950170-21-001975 001-33038 211298915 34 164363 1 1
2021-09-27 8-K 8-K 2.05,7.01,9.01 0000950170-21-001903 001-33038 211281712 34 212563 1 1
2021-09-03 4 FORM 4 SUBMISSION 0001209191-21-054829 5145
2021-09-03 4 FORM 4 SUBMISSION 0001209191-21-054828 7530
2021-09-03 4 FORM 4 SUBMISSION 0001209191-21-054825 7542
2021-09-03 4 FORM 4 SUBMISSION 0001209191-21-054824 5140
2021-08-31 4 FORM 4 SUBMISSION 0001209191-21-054089 7450
2021-08-31 3 FORM 3 SUBMISSION 0001209191-21-054087 7326
2021-08-30 8-K 8-K 5.02,9.01 0001193125-21-260859 001-33038 211224601 34 300026 1 1
2021-08-13 10-Q 10-Q 0000950170-21-001446 001-33038 211173138 34 6680869 1 1
2021-08-12 8-K 8-K 1.01,2.03,3.02 0001193125-21-244836 001-33038 211168435 34 164772 1 1
2021-08-09 NT 10-Q NT 10-Q 0001193125-21-240604 001-33038 211157369 34 22483
2021-08-09 8-K 8-K 2.02,9.01 0001193125-21-240592 001-33038 211157341 34 190317 1 1
2021-05-21 8-K 8-K 3.03,5.02,5.03,5.07,7.01,9.01 0001193125-21-169242 001-33038 21948925 34 220584 1 1
2021-05-19 4 FORM 4 SUBMISSION 0001209191-21-034027 4943
2021-05-13 8-K 8-K 5.02 0001193125-21-160554 001-33038 21920116 34 148577 1 1
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030746 12321
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030745 12276
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030743 9400
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030742 11385
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030740 7064
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030738 7031
2021-05-06 4 FORM 4 SUBMISSION 0001209191-21-030737 7045
2021-05-06 10-Q 10-Q 0001193125-21-153365 001-33038 21898450 34 4668032 1 1
2021-05-06 8-K 8-K 2.02,2.05,9.01 0001193125-21-153304 001-33038 21898028 34 207019 1 1
2021-04-09 8-K 8-K 5.02,9.01 0001193125-21-111091 001-33038 21816616 34 418529 1 1
2021-04-07 DEFA14A DEFA14A 0001193125-21-108287 001-33038 21810830 34 936509
2021-04-07 DEF 14A DEF 14A 0001193125-21-108283 001-33038 21810822 34 2286272
2021-03-31 3 FORM 3 SUBMISSION 0001209191-21-023775 9426
2021-03-25 PRE 14A PRE 14A 0001193125-21-094507 001-33038 21772823 34 2280982
2021-03-25 8-K 8-K 5.02 0001193125-21-094494 001-33038 21772773 34 148949 1 1
2021-03-22 3 FORM 3 SUBMISSION 0001209191-21-022396 10717
2021-03-22 3 FORM 3 SUBMISSION 0001209191-21-022395 10669
2021-03-22 3 FORM 3 SUBMISSION 0001209191-21-022394 11197
2021-03-11 SEC STAFF LETTER filename1.pdf 9999999997-21-000656 276082
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018632 7248
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018630 7248
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018629 7174
2021-03-08 4 FORM 4 SUBMISSION 0001209191-21-018628 7290
2021-03-02 8-K 8-K 5.02,9.01 0001193125-21-065465 001-33038 21703431 34 267301 1 1
2021-03-01 10-K 10-K 0001193125-21-063387 001-33038 21697628 34 12668323 1 1
2021-02-26 3 FORM 3 SUBMISSION 0001209191-21-014839 7284
2021-02-25 8-K 8-K 2.02,9.01 0001193125-21-056943 001-33038 21680259 34 218598 1 1
2021-02-23 8-K 8-K 5.02,9.01 0001193125-21-052339 001-33038 21665442 34 215699 1 1
2021-02-16 SC 13G/A SCHEDULE 13G 0001804350-21-000001 005-79364 21635373 34 17761
2021-02-16 SC 13G/A MILLER VALUE PARTNERS, LLC 0001085146-21-000853 005-79364 21633793 34 49280
2021-02-10 SC 13G/A SCHEDULE 13G/A 0001104659-21-019475 005-79364 21612403 34 13998
2021-02-10 SEC STAFF LETTER filename1.pdf 9999999997-21-000619 277145
2021-02-05 8-K 8-K 1.01,5.02,8.01,9.01 0001193125-21-030026 001-33038 21594024 34 275642 1 1
2021-02-01 SC 13G/A us98973p1012_013121.txt 0000834237-21-005571 005-79364 21574584 34 13542
2021-01-14 8-K 8-K 7.01,9.01 0001193125-21-008651 001-33038 21527538 34 9965772 1 1
2021-01-12 4 FORM 4 SUBMISSION 0001209191-21-003245 5481
2021-01-12 4 FORM 4 SUBMISSION 0001209191-21-003244 4966
2021-01-12 4 FORM 4 SUBMISSION 0001209191-21-003242 5481
2021-01-07 SC 13G d8718385_13-g.htm 0000919574-21-000073 005-79364 21514436 34 124924
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002174 5489
2021-01-06 4 FORM 4 SUBMISSION 0001209191-21-002171 5514
2020-12-30 8-K 8-K 3.01 0001193125-20-329908 001-33038 201426492 34 151662 1 1
2020-12-18 8-K CURRENT REPORT 3.01,5.02,5.03,5.07,8.01,9.01 0001213900-20-043385 001-33038 201398071 34 307582 1 1
2020-12-17 DFAN14A dfan14a12766002_12172020.htm 0000921895-20-003264 001-33038 201396767 34 190032
2020-12-17 DEFA14A DEFA14A 0001213900-20-043100 001-33038 201393454 34 29843
2020-12-15 8-K 8-K 5.02,9.01 0001193125-20-318183 001-33038 201390217 34 168312 1 1
2020-12-14 DFAN14A dfan14a12766002_12142020.htm 0000921895-20-003232 001-33038 201386228 34 104320
2020-12-14 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-042404 001-33038 201385143 34 44258
2020-12-11 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-042162 001-33038 201382526 34 62160
2020-12-08 DFAN14A dfan14a12766002_12072020.htm 0000921895-20-003189 001-33038 201375996 34 142388
2020-12-08 8-K 8-K 5.02 0001193125-20-312748 001-33038 201375480 34 149024 1 1
2020-12-04 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-041145 001-33038 201370739 34 77303
2020-12-04 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-041143 001-33038 201370735 34 3040058
2020-12-03 DFAN14A dfan14a12766002_12032020.htm 0000921895-20-003169 001-33038 201366810 34 128761
2020-12-02 DFAN14A dfan14a12766002_12022020.htm 0000921895-20-003159 001-33038 201363748 34 1548520
2020-11-30 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-040038 001-33038 201359122 34 22892354
2020-11-30 DFAN14A dfan14a12766002_11302020.htm 0000921895-20-003134 001-33038 201358781 34 127682
2020-11-27 DEFA14A FORM DEFA14A 0001213900-20-039716 001-33038 201355954 34 42947
2020-11-27 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-039714 001-33038 201355940 34 83194
2020-11-27 DFAN14A e620106_dfan14a-ziopharm.htm 0000921895-20-003122 001-33038 201354921 34 106079
2020-11-24 DFAN14A dfan14a12766002_11242020.htm 0000921895-20-003103 001-33038 201344587 34 137891
2020-11-23 DFAN14A dfan14a12766002_11232020.htm 0000921895-20-003097 001-33038 201339040 34 3615797
2020-11-20 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-038408 001-33038 201331222 34 42025
2020-11-20 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-038287 001-33038 201329759 34 7127241
2020-11-19 3 FORM 3 SUBMISSION 0001209191-20-059429 7203
2020-11-19 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-038254 001-33038 201329349 34 521430
2020-11-19 8-K CURRENT REPORT 5.02,9.01 0001213900-20-038252 001-33038 201329334 34 264743 1 1
2020-11-19 DFAN14A dfan14a12766002_11192020.htm 0000921895-20-003052 001-33038 201328968 34 2718013
2020-11-18 SC 13G/A SC 13G/A 0001104659-20-126942 005-79364 201326099 34 187758
2020-11-18 DFAN14A dfan14a12766002_11182020.htm 0000921895-20-003037 001-33038 201325991 34 2655588
2020-11-16 DFAN14A dfan14a12766002_11162020.htm 0000921895-20-003000 001-33038 201315784 34 125669
2020-11-13 DFAN14A dfan14a12766002_11132020.htm 0000921895-20-002944 001-33038 201312314 34 121009
2020-11-12 DFAN14A dfan14a12766002_11122020.htm 0000921895-20-002893 001-33038 201306163 34 159566
2020-11-05 DFAN14A dfan14a12766002_11052020.htm 0000921895-20-002806 001-33038 201291573 34 1024561
2020-11-05 8-K 8-K 2.02,7.01,9.01 0001193125-20-286826 001-33038 201290469 34 5103402 1 1
2020-11-05 10-Q 10-Q 0001193125-20-286807 001-33038 201290342 34 5174890 1 1
2020-11-04 DFRN14A dfrn14a12766002_11042020.htm 0000921895-20-002790 001-33038 201286743 34 101607
2020-11-02 DEFA14A FORM DEFA14A 0001213900-20-034575 001-33038 201281304 34 5021436
2020-11-02 DFAN14A dfan14a12766002_11022020.htm 0000921895-20-002762 001-33038 201280455 34 42407
2020-11-02 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-034421 001-33038 201279161 34 76044
2020-11-02 DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-20-034417 001-33038 201279148 34 116381
2020-11-02 DEFC14A defc1020_ziopharm.htm 0001213900-20-034356 001-33038 201279067 34 5077023
2020-10-30 DEFC14A defc14a12766002_10302020.htm 0000921895-20-002751 001-33038 201277925 34 513420
2020-10-29 PRRN14A prrn14a12766002_10292020.htm 0000921895-20-002726 001-33038 201273249 34 513939
2020-10-28 PRRN14A prrn14a12766002_10282020.htm 0000921895-20-002713 001-33038 201269628 34 511986
2020-10-28 UPLOAD filename1.pdf 0000000000-20-010194 243017
2020-10-27 PRER14A PRELIMINARY REVISED PROXY STATEMENT 0001213900-20-033544 001-33038 201264293 34 1648414
2020-10-27 CORRESP filename1.htm 0001213900-20-033522 33296
2020-10-27 UPLOAD filename1.pdf 0000000000-20-010137 234924
2020-10-26 PRRN14A prrn14a12766002_10262020.htm 0000921895-20-002699 001-33038 201261533 34 469967
2020-10-22 UPLOAD filename1.pdf 0000000000-20-010022 267459
2020-10-21 PREC14A PRELIMINARY PROXY STATEMENT 0001213900-20-032558 001-33038 201251093 34 812780
2020-10-16 DEFA14A DEFA14A 0001193125-20-271219 001-33038 201244623 34 30742
2020-10-16 PREC14A prec14a12766002_10142020.htm 0000921895-20-002619 001-33038 201243485 34 466938
2020-10-13 4 FORM 4 SUBMISSION 0001209191-20-054667 5491
2020-10-01 8-K 8-K 1.01 0001193125-20-260571 001-33038 201214528 34 150888 1 1
2020-09-28 3 FORM 3 SUBMISSION 0001209191-20-052214 7157
2020-09-22 8-K 8-K 5.02,5.03,9.01 0001193125-20-250711 001-33038 201187949 34 268386 1 1
2020-08-06 S-8 S-8 0001193125-20-212035 333-241698 201082608 33 74576
2020-08-06 8-K 8-K 2.02,9.01 0001193125-20-211899 001-33038 201081720 34 212158 1 1
2020-08-06 10-Q 10-Q 0001193125-20-211865 001-33038 201081430 34 4994060 1 1
2020-07-24 8-K 8-K 5.02 0001193125-20-198249 001-33038 201045270 34 155381 1 1
2020-07-22 4 FORM 4 SUBMISSION 0001209191-20-043323 5352
2020-07-22 3 FORM 3 SUBMISSION 0001209191-20-043319 7202
2020-07-01 8-K 8-K 5.02,5.07,9.01 0001193125-20-184639 001-33038 201004005 34 407000 1 1
2020-05-29 8-K 8-K 5.02,8.01,9.01 0001193125-20-155032 001-33038 20924089 34 280270 1 1
2020-05-18 DEFA14A DEFA14A 0001193125-20-145101 001-33038 20890233 34 565214
2020-05-18 DEF 14A DEF 14A 0001193125-20-145086 001-33038 20890145 34 1899390
2020-05-08 PRE 14A PRE 14A 0001193125-20-137017 001-33038 20858812 34 1898750
2020-05-08 S-8 S-8 0001193125-20-136509 333-238090 20858005 33 148149
2020-05-07 8-K 8-K 2.02,9.01 0001193125-20-136234 001-33038 20856449 34 216534 1 1
2020-05-07 10-Q 10-Q 0001193125-20-136200 001-33038 20856174 34 4845522 1 1
2020-04-29 10-K/A 10-K/A 0001193125-20-126370 001-33038 20831100 34 570181
2020-03-02 8-K 8-K 2.02,9.01 0001193125-20-058964 001-33038 20677203 34 96168
2020-03-02 10-K 10-K 0001193125-20-058863 001-33038 20676770 34 9713106 1
2020-02-24 SC 13G SCHEDULE 13G 0001804350-20-000001 005-79364 20643197 34 89800
2020-02-14 SC 13G/A msdpartnersziopharm13ga.htm 0001123292-20-000273 005-79364 20621293 34 338479
2020-02-14 SC 13G/A MILLER VALUE PARTNERS, LLC 0001085146-20-000816 005-79364 20618173 34 49288
2020-02-11 SC 13G SCHEDULE 13G 0001104659-20-016345 005-79364 20597237 34 13788
2020-02-06 8-K 8-K 1.01,8.01 0001193125-20-026318 001-33038 20581449 34 316873
2020-02-06 SC 13G/A us98973p1012_020520.txt 0000834237-20-006746 005-79364 20581262 34 13462
2020-02-05 424B5 424B5 0001193125-20-025491 333-232283 20579817 33 811893
2020-02-05 8-K 8-K 2.02,8.01,9.01 0001193125-20-024518 001-33038 20576219 34 122046
2020-02-04 424B5 424B5 0001193125-20-024354 333-232283 20575070 33 807290
2020-01-31 4 FORM 4 SUBMISSION 0001209191-20-005789 7280
2020-01-31 4 FORM 4 SUBMISSION 0001209191-20-005787 7272
2020-01-31 4 FORM 4 SUBMISSION 0001209191-20-005785 4841
2020-01-31 4 FORM 4 SUBMISSION 0001209191-20-005783 7234
2020-01-31 4 FORM 4 SUBMISSION 0001209191-20-005781 7244

Latest XBRL company facts

One latest value per concept from companyfacts (348 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 4.21M 2026-11-16 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
dei EntityPublicFloat Entity Public Float USD 9.61M 2025-06-30 2025 FY 10-K/A 2026-04-30 0001193125-26-197838
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 131,938 2025-01-01 2025-12-31 PRE 14A 2026-11-13 0001193125-26-461060
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 143,118 2025-01-01 2025-12-31 PRE 14A 2026-11-13 0001193125-26-461060
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 3.27 2025-01-01 2025-12-31 PRE 14A 2026-11-13 0001193125-26-461060
ffd NetFeeAmt NetFeeAmt USD 57,508.48 2026-11-10 S-3 2026-11-13 0001193125-26-458953
ffd TtlFeeAmt TtlFeeAmt USD 57,508.48 2026-11-10 S-3 2026-11-13 0001193125-26-458953
ffd TtlOfferingAmt TtlOfferingAmt USD 661.02M 2026-11-10 S-3 2026-11-13 0001193125-26-458953
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-10 S-3 2026-11-13 0001193125-26-458953
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-10 S-3 2026-11-13 0001193125-26-458953
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 796,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AccruedBonusesCurrent Accrued Bonuses, Current USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 54,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 151,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AccruedPayrollTaxesCurrent Accrued Payroll Taxes, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-30 0000950170-22-004972
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 23,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap AccruedRentCurrent Accrued Rent, Current USD 56,000 2016-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 227,000 2021-12-31 2021 FY 10-K 2022-03-30 0000950170-22-004972
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 7,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 928.32M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 154,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 2.70M 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-06 0001193125-21-153365
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 1.02M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap AdministrativeFeesExpense Administrative Fees Expense USD 250,000 2025-07-01 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 3.51M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap AllocatedShareBasedCompensationExpenseNetOfTax Share-based Payment Arrangement, Expense, after Tax USD 6.83M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 322,000 2016-03-31 2016 Q1 10-Q 2016-05-10 0001193125-16-585559
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 749,932 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap Assets Assets USD 1.92M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap AssetsCurrent Assets, Current USD 1.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap BankingFeesAndCommissions Banking Fees and Commissions (Deprecated 2018-01-31) USD 2.20M 2010-05-01 2010-05-27 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-15 0000950170-24-060075
us-gaap CapitalizedComputerSoftwareGross Capitalized Computer Software, Gross USD 886,000 2015-12-31 2015 FY 10-K 2016-02-24 0001193125-16-475875
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 615,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 66.79M 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -10.11M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 615,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD -30.54M 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-08 0001193125-18-242705
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -770,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Class of Warrant or Right, Exercise Price of Warrants or Rights (Deprecated 2014-01-31) USD/Right 5.75 2007-02-23 2013 Q3 10-Q 2013-10-22 0001193125-13-406591
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 9.63 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 18.94M 2018-11-11 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 106,452 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 31.12M 2021-02-24 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 50.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 3.32M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 3.32M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap CommonStockValue Common Stock, Value, Issued USD 3,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ContractRevenueCost Contract Revenue Cost (Deprecated 2018-01-31) USD 116.25M 2003-09-09 2011-09-30 2011 Q3 10-Q 2011-11-03 0001144204-11-061165
us-gaap ContractsRevenue Contracts Revenue (Deprecated 2018-01-31) USD 146,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 692,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap CumulativeEffectOnRetainedEarningsNetOfTax1 Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) USD -8.13M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 54,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate pure 0.045 2021-08-06 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 16.77M 2022-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap DeferredCompensationArrangementWithIndividualSharesIssued Deferred Compensation Arrangement with Individual, Shares Issued shares 446,428 2019-01-01 2019-01-06 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap DeferredRentCredit Deferred Rent Credit USD 17,000 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap DeferredRentCreditCurrent Deferred Rent Credit, Current USD 13,000 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 4,000 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap DeferredRevenue Deferred Revenue USD 41.50M 2017-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 6.39M 2017-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 35.14M 2017-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 0 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 213.58M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 163.25M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration USD 436.00M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD -20,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 40.34M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits USD 766,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 213.58M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityBadDebtReserveForTaxPurposesOfQualifiedLender Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Bad Debt Reserve for Tax Purposes of Qualified Lender USD 57,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 13,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DepositsAssetsNoncurrent Deposits Assets, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap Depreciation Depreciation USD 25,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 412,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-09 0001193125-18-323155
us-gaap DerivativeFairValueOfDerivativeLiability Derivative Liability, Fair Value, Gross Liability USD 0 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 2.42M 2017-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap DerivativeLiabilityFairValueOfCollateral Derivative Liability, Fair Value of Collateral USD 31,000 2025-06-09 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 350.54M 2014-03-31 2014 Q1 10-Q 2014-05-08 0001193125-14-189905
us-gaap DilutiveSecurities Dilutive Securities, Effect on Basic Earnings Per Share USD 201.49M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 17.00M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DueToRelatedPartiesCurrentAndNoncurrent Due to Related Parties USD 100,000 2019-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap DueToRelatedPartiesNoncurrent Due to Related Parties, Noncurrent USD 119.05M 2016-06-30 2016 Q2 10-Q 2016-08-09 0001193125-16-676724
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.05 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0000950170-22-009942
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.07 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.05 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap EmployeeBenefitsAndShareBasedCompensationNoncash Employee Benefit and Share-based Payment Arrangement, Noncash USD 154,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 8.50M 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount USD 2,400 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 5.10M 2015-09-30 2015 Q3 10-Q 2015-11-02 0001193125-15-362281
us-gaap EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-based Payment Arrangement, Expense, Tax Benefit USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap FairValueAssumptionsRiskFreeInterestRate Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) pure 0.05 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -600,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-02-24 0001193125-16-475875
us-gaap GainLossOnSaleOfBusiness Gain (Loss) on Disposition of Business USD -800,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-02-24 0001193125-16-475875
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 1.68M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 305,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -859,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 18,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 196,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 183,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -49,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -146,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD -125,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -146,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-09 0001193125-18-323155
us-gaap IncreaseDecreaseInDepositOtherAssets Increase (Decrease) in Deposit Assets USD -4,000 2013-01-01 2013-12-31 2014 FY 10-K 2015-02-26 0001193125-15-065956
us-gaap IncreaseDecreaseInDeposits Increase (Decrease) in Deposits USD -2,000 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-08 0001193125-19-216056
us-gaap IncreaseDecreaseInOtherDeferredLiability Increase (Decrease) in Other Deferred Liability USD 19,000 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-10 0001193125-15-284805
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD -500,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 7,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001193125-19-287259
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -250,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap IncreaseDecreaseInReceivables Increase (Decrease) in Receivables USD -3,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 201,362 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap InterestExpense Interest Expense USD 0 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0000950170-24-097142
us-gaap InterestExpenseDebt Interest Expense, Debt USD 1.90M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD -444,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 0 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions USD 1.00M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap IssuanceOfStockAndWarrantsForServicesOrClaims Issuance of Stock and Warrants for Services or Claims USD 67.28M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap LandSubjectToGroundLeases Land Subject to Ground Leases sqft 9,800 2021-04-22 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 5,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap LeaseCost Lease, Cost USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 990,000 2015-12-31 2015 FY 10-K 2016-02-24 0001193125-16-475875
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 3.24M 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 31,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four USD 375,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three USD 364,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two USD 353,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months USD 896,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 757,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 158,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 712,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 804,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 780,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 273,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 496,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths Lessor, Operating Lease, Payment to be Received, Year One USD 200,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LessorOperatingLeasePaymentsToBeReceivedThreeYears Lessor, Operating Lease, Payment to be Received, Year Three USD 100,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap LessorOperatingLeasePaymentsToBeReceivedTwoYears Lessor, Operating Lease, Payment to be Received, Year Two USD 200,000 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap Liabilities Liabilities USD 947,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 1.92M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap LiabilitiesAssumed1 Liabilities Assumed USD 119.05M 2016-01-01 2016-06-30 2016 Q2 10-Q 2016-08-09 0001193125-16-676724
us-gaap LiabilitiesCurrent Liabilities, Current USD 947,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap LitigationSettlementExpense Litigation Settlement, Expense USD 1.00M 2023-10-20 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap LongTermPurchaseCommitmentAmount Long-term Purchase Commitment, Amount USD 50.00M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap LossContingencyAccrualCarryingValueCurrent Loss Contingency, Accrual, Current USD 1.00M 2023-09-30 2023 Q3 10-Q 2023-11-14 0000950170-23-063354
us-gaap LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value USD 3.20M 2023-03-17 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap MachineryAndEquipmentGross Machinery and Equipment, Gross USD 572,000 2015-12-31 2015 FY 10-K 2016-02-24 0001193125-16-475875
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 986,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD -731,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -150,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -1.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -18.96M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001193125-18-159174
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -2.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -2.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets (Deprecated 2012-01-31) USD -72,000 2009-01-01 2009-12-31 2011 FY 10-K 2012-02-29 0001144204-12-012003
us-gaap NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1 New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets (Deprecated 2020-01-31) USD -122,000 2017-03-31 2017 Q1 10-Q 2017-05-01 0001193125-17-151749
us-gaap NoninterestExpenseTransferAgentAndCustodianFees Noninterest Expense Transfer Agent and Custodian Fees USD 455,000 2009-08-16 2009-09-15 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap OperatingCostsAndExpenses Operating Costs and Expenses USD 22.77M 2020-10-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap OperatingExpenses Operating Expenses USD 2.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -2.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap OperatingLeaseCost Operating Lease, Cost USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 600,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 2.75M 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 0 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 4.71M 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap OperatingLeasePayments Operating Lease, Payments USD 400,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap OperatingLeaseResidualValueOfLeasedAsset Operating Lease, Residual Value of Leased Asset USD 1.40M 2021-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 1.95M 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 723,000 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals USD 278,000 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 0 2014-12-31 2014 FY 10-K 2015-02-26 0001193125-15-065956
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 489,000 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 488,000 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 736,000 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 424,000 2012-12-31 2012 FY 10-K 2013-03-18 0001193125-13-112464
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 723,000 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 700,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap OtherAccruedLiabilitiesCurrentAndNoncurrent Other Accrued Liabilities USD 500,000 2021-12-31 2021 FY 10-K 2022-03-30 0000950170-22-004972
us-gaap OtherAdditionalCapital Other Additional Capital USD 3.60M 2013-12-31 2014 FY 10-K 2015-02-26 0001193125-15-065956
us-gaap OtherAssetImpairmentCharges Other Asset Impairment Charges USD 100,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap OtherEmployeeRelatedLiabilitiesCurrent Other Employee-related Liabilities, Current USD 474,000 2012-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 11.96M 2003-09-10 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap OtherNonoperatingGainsLosses Other Nonoperating Gains (Losses) USD 13.75M 2003-09-10 2013-09-30 2013 Q3 10-Q 2013-10-22 0001193125-13-406591
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap PaymentsForCommissions Payments for Commissions USD 1.70M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap PaymentsForRepurchaseOfEquity Payments for Repurchase of Equity USD 1.27M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-09 0001193125-18-323155
us-gaap PaymentsForRepurchaseOfOtherEquity Payments for Repurchase of Other Equity USD 246,000 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-10 0001193125-15-284805
us-gaap PaymentsForUnderwritingExpense Payments for Underwriting Expense USD 2.80M 2009-11-01 2009-12-04 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap PaymentsOfDebtExtinguishmentCosts Payment for Debt Extinguishment or Debt Prepayment Cost USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap PaymentsOfDistributionsToAffiliates Payments of Distributions to Affiliates USD 425,000 2005-08-14 2005-09-13 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap PaymentsToAcquireInterestInJointVenture Payments to Acquire Interest in Joint Venture USD 35.00M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap PostemploymentBenefitsPeriodExpense Postemployment Benefits, Period Expense USD 3.50M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 109,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 17.00M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2021-03-31 2021 Q1 10-Q 2021-05-06 0001193125-21-153365
us-gaap PreferredStockRedemptionDiscount Preferred Stock Redemption Discount USD 207.36M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 30.00M 2021-03-31 2021 Q1 10-Q 2021-05-06 0001193125-21-153365
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2016-09-30 2016 Q3 10-Q 2016-11-09 0001193125-16-764305
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2016-09-30 2016 Q3 10-Q 2016-11-09 0001193125-16-764305
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 461,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap PrepaidExpenseAndOtherAssetsNoncurrent Prepaid Expense and Other Assets, Noncurrent USD 776,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ProceedsFromContributedCapital Proceeds from Contributed Capital USD 500,000 2003-09-10 2014-03-31 2014 Q1 10-Q 2014-05-08 0001193125-14-189905
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 6.08M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-07 0000950170-23-006377
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 16.76M 2003-09-10 2014-03-31 2014 Q1 10-Q 2014-05-08 0001193125-14-189905
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 52.50M 2019-09-12 2024 Q1 10-Q 2024-05-15 0000950170-24-060075
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 788,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap ProceedsFromRepaymentsOfLinesOfCredit Proceeds from (Repayments of) Lines of Credit USD 70,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ProceedsFromRepaymentsOfRelatedPartyDebt Proceeds from (Repayments of) Related Party Debt USD -5.41M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 52.50M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -40.64M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-09 0001193125-18-323155
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 98,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 66,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap PurchaseCommitmentRemainingMinimumAmountCommitted Purchase Commitment, Remaining Minimum Amount Committed USD 19.00M 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ReceivablesNetCurrent Receivables, Net, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction USD 207.36M 2018-10-01 2018-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap RepaymentsOfRelatedPartyDebt Repayments of Related Party Debt USD 180,000 2006-11-19 2006-12-18 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 1.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap RestrictedCash Restricted Cash USD 13.90M 2023-03-31 2023 Q1 10-Q 2023-05-10 0000950170-23-020088
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 691,000 2012-12-31 2012 FY 10-K 2013-03-18 0001193125-13-112464
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 388,000 2016-12-31 2018 FY 10-K 2019-03-05 0001193125-19-063978
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Position 65 2013-04-03 2014 Q3 10-Q 2014-10-30 0001193125-14-389572
us-gaap RestructuringCharges Restructuring Charges USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap RestructuringCosts Restructuring Costs USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -927.35M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 398,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount USD 57.50M 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap Revenues Revenues USD 15.90M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap RoyaltyExpense Royalty Expense USD 0 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0000950170-24-097142
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-30 0000950170-22-004972
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 4.893 2017-05-11 2019 FY 10-K 2020-03-02 0001193125-20-058863
us-gaap SecurityDeposit Security Deposit USD 2,000 2019-06-30 2019 Q2 10-Q 2019-08-08 0001193125-19-216056
us-gaap SeveranceCosts1 Severance Costs USD 1.30M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 562,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period shares 163,747 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value USD/shares 4.42 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 805,900 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 4.34 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 352,865 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 4.38 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 292,399 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value USD/shares 4.31 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.251 2025-04-01 2025-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352421
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.27 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 1.193 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.042 2025-04-01 2025-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-352421
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.042 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.041 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized shares 45,823 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-18 0001193125-13-112464
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 484,156 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 133,233 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 32.66 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 26,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 3,085 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 506,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-09 0001193125-18-323155
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.16 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-14 0000950170-25-108887
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 219,400 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 21.38 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 3.32M 2016-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 6.71M 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 4.4 2016-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 3.44M 2016-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 10,417 2021-04-29 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 201,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-02 0001193125-15-362281
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 168.52 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap SharePrice Share Price USD/shares 3.5 2013-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 0 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap SignificantPurchaseCommitmentRemainingMinimumAmountCommitted Purchase Commitment, Remaining Minimum Amount Committed (Deprecated 2013-01-31) USD 29.00M 2012-12-31 2012 FY 10-K 2013-03-18 0001193125-13-112464
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 971,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap StockIssued1 Stock Issued USD 67.28M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 2.81M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 408,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 916,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Stock Issued During Period, Value, Restricted Stock Award, Forfeitures USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003463
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 1,000 2021-01-01 2021-06-30 2022 Q2 10-Q 2022-08-15 0000950170-22-017225
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 0 2020-01-01 2020-06-30 2021 Q2 10-Q 2021-08-13 0000950170-21-001446
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 21,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap StockRedeemedOrCalledDuringPeriodValue Stock Redeemed or Called During Period, Value USD -370,000 2019-01-01 2019-09-30 2020 Q3 10-Q 2020-11-05 0001193125-20-286807
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD 207.36M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 45,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap TangibleAssetImpairmentCharges Tangible Asset Impairment Charges USD 4.80M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047758
us-gaap TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount USD 0 2024-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap UnrealizedGainLossOnDerivatives Unrealized Gain (Loss) on Derivatives USD -3.53M 2016-10-01 2016-12-31 2016 FY 10-K 2017-02-16 0001193125-17-046668
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 238,000 2014-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities USD 0 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 0 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD -37,000 2013-01-01 2013-12-31 2014 FY 10-K 2015-02-26 0001193125-15-065956
us-gaap UnrecognizedTaxBenefitsPeriodIncreaseDecrease Unrecognized Tax Benefits, Period Increase (Decrease) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-04-01 0000950170-24-038868
us-gaap UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations USD 0 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-01 0001193125-18-067077
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 303,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-134720
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 18.87M 2008-12-31 2013 FY 10-K 2014-03-03 0001193125-14-080282
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 2.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 214.95M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-16 0000950170-22-009942
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 2.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463638
us-gaap WorkersCompensationLiabilityCurrent Workers' Compensation Liability, Current USD 3.30M 2020-12-31 2020 FY 10-K 2021-03-01 0001193125-21-063387

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →